Eton Pharmaceuticals Inc. (ETON) is carving out a strong position in rare disease care, building a fast-growing portfolio of treatments backed by a consistent track record of successful commercialization.
The company has 10 commercial products - INCRELEX for Severe Primary Insulin-Like Growth Factor 1 Deficiency; ALKINDI SPRINKLE for Pediatric Adrenal Insufficiency; KHINDIVI for Pediatric Adrenal Insufficiency; GALZIN for Wilson disease; PKU GOLIKE for Phenylketonuria; Carglumic Acid for Hyperammonemia; Betaine Anhydrous for Homocystinuria; DESMODA for Diabetes Insipidus; HEMANGEOL for Infantile Hemangioma; and Nitisinone for Hereditary Tyrosinemia Type 1 (HT-1).
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.